Biotech industry aims to avoid backlash from GMO-wary consumers as CRISPR-edited crops near mass commercialization

Screen Shot at AM

The biotechnology industry wants to avoid repeating mistakes with gene editing that it made nearly three decades ago with transgenic crops.

Back when such crops were first being commercialized, the problem wasnโ€™t with the technology but with how the industry rolled them out to the public, said Roxi Beck, director of consumer engagement with the Center for Food Integrity.

Biotech companies primarily focused on explaining the benefits to farmers, rather than shoppers who might be leery of plants that incorporate genes from foreign organisms …. โ€œThey didnโ€™t know they had to think about the customerโ€™s customerโ€™s customer.โ€

Unlike transgenic biotechnology, gene editing involves removing or changing DNA sequences found naturally in the plant or animal.

It can be used to calibrate messages about gene editing, since consumers โ€œabsolutely donโ€™t want an academic explanationโ€ but they are also skeptical of oversimplification, Beck said. โ€œWe donโ€™t want to make it seem as if we were talking down to them.โ€

For example, saying the process of cutting and altering gene sequences was found to โ€œsound sinisterโ€ while comparisons to splicing film or editing text with a word processor were thought to be condescending, she said. โ€œThey want that level of transparency.โ€

Read the original article

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosateโ€”the world's most heavily-used herbicideโ€”pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Picture1-5
Science Disinformation Gap: The transatlantic battle over social media and censorship
Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Foodโ€”health harming industries or life-saving innovators?
ChatGPT Image May 10, 2026, 08_16_59 PM 2
Overmedicalization? RFK Jr.โ€™s antidepressant crackdown raises conflict questions over his fee stake in Wisner Baum, the tort firm built on suing drug makers
Screenshot-2026-05-12-at-9.58.31-PM
'He seems fine': Marty Makary out as FDA commissioner
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
Screenshot-2026-05-12-at-10.05.11-AM
Pro-vaccine โ€œheroโ€ vs. an anti-vax โ€œvillainโ€: โ€˜Bad Vaxxโ€™ video stirs MAHA backlash
Screenshot-2026-05-11-104424
Hantavirus outbreak research: Trump administration shut down study last year on rodent-to-human transmission
ChatGPT Image May 12, 2026, 10_19_00 AM 2
Viewpointโ€” 'Muscular governance': How authoritarianism is surging corporate-linked energy misinformation
Picture1-14
When superbugs threaten vulnerable children: Can AI help solve antibiotic resistance?
S
As vaccine rejectionism spreads, measles may be taking a more dangerous turn
Screenshot-2026-05-01-at-1.29.41-PM
Viewpoint: What happens when whole grains meet modern food manufacturing? Labels donโ€™t tell the whole story.
Screenshot 2026-05-11 at 11.30
Despite politicized disinformation, Midwest AI data centers are fueling a solar energy boom
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.